problendoПроблемы ЭндокринологииProblems of Endocrinology0375-96602308-1430Endocrinology Research Centre10.14341/probl13148problendo-13148Research ArticleРепродуктивная эндокринологияReproductive EndocrinologyАндрогены и болезнь Паркинсона: роль у человека и в экспериментеAndrogens and Parkinson’s disease: the role in humans and in experimenthttps://orcid.org/0000-0001-6197-195XХамадьяноваА. У.HamadyanovaA. U.

Хамадьянова Аида Ульфатовна

119021, г. Москва, переулок Хользунова, д. 7

SPIN-код: 4425-5371

Aida U. Hamadyanova

119021, Moscow, pereulok Holzunova 7

SPIN-код: 4425-5371

sagidullin12@bk.ruhttps://orcid.org/0000-0002-2405-1801КузнецовК. О.KuznetsovK. O.

Кузнецов Кирилл Олегович

119021, г. Москва, переулок Хользунова, д. 7

SPIN-код: 3053-3773

Kirill O. Kuznetsov

119021, Moscow, pereulok Holzunova 7

SPIN-код: 3053-3773

kirillkuznetsov@aol.comhttps://orcid.org/0000-0002-8719-608XГайфуллинаЭ. И.GaifullinaE. I.

Гайфуллина Энже Ильнуровна

119021, г. Москва, переулок Хользунова, д. 7

SPIN-код: 5232-0354

Enzhe I. Gaifullina

119021, Moscow, pereulok Holzunova 7

SPIN-код: 5232-0354

enzhegaifullina@mail.ruhttps://orcid.org/0000-0001-7733-9772КаландинД. А.KalandinD. A.

Каландин Дмитрий Андреевич

Санкт-Петербург

SPIN-код: 7153-8561

Dmitriy A. Kalandin

119021, Moscow, pereulok Holzunova 7

SPIN-код: 7153-8561

dm.keni@yandex.ruhttps://orcid.org/0000-0003-0345-3489ХамидуллинаР. Р.KhamidullinaR. R.

Хамидуллина Радмила Рафитовна

119021, г. Москва, переулок Хользунова, д. 7

SPIN-код: 7327-4655

Radmila R. Khamudillina

119021, Moscow, pereulok Holzunova 7

SPIN-код: 7327-4655

khamidullina_radmila@mail.ruhttps://orcid.org/0000-0002-3501-7756ХалитоваИ. Ф.KhalitovaI. F.

Халитова Ильсина Фаргатовна

119021, г. Москва, переулок Хользунова, д. 7

SPIN-код: 6339-3531

Ilsina F. Khalitova

119021, Moscow, pereulok Holzunova 7

SPIN-код: 6339-3531

ilsina.khalitova@yandex.ruhttps://orcid.org/0000-0003-3275-5013ФаизовР. М.FaizovR. M.

Фаизов Радмир Мидхатович

119021, г. Москва, переулок Хользунова, д. 7

SPIN-код: 6447-2557

Radmir M. Faizov

119021, Moscow, pereulok Holzunova 7

SPIN-код: 6447-2557

fradmir177@gmail.comhttps://orcid.org/0000-0001-7440-3943КамалетдиноваН. О.KamaletdinovaN. O.

Камалетдинова Нелли Олеговна

119021, г. Москва, переулок Хользунова, д. 7

SPIN-код: 7394-6220

Nelli O. Kamaletdinova

119021, Moscow, pereulok Holzunova 7

SPIN-код: 7394-6220

nelli-kamaletdinova@mail.ruhttps://orcid.org/0000-0001-8513-2464АслановаБ. Ф.AslanovaB. F.

Асланова Бикеханум Фикретдиновна

Ростов-на-Дону

SPIN-код: 8023-9633

Bikekhanum F. Aslanova

Rostov-on-Don

SPIN-код: 8023-9633

bikesha99@gmail.comhttps://orcid.org/0000-0003-4191-8638НакиеваА. Г.NakievaA. G.

Накиева Аделина Гарифовна

119021, г. Москва, переулок Хользунова, д. 7

SPIN-код: 7722-4354

Adelina G. Nakieva

119021, Moscow, pereulok Holzunova 7

SPIN-код: 7722-4354

full-house8@yandex.ruhttps://orcid.org/0000-0002-2357-781XБурангуловаЛ. Э.BurangulovaL. E.

Бурангулова Лиана Эльвировна

119021, г. Москва, переулок Хользунова, д. 7

SPIN-код: 6832-9521

Liana E. Burangulova

119021, Moscow, pereulok Holzunova 7

SPIN-код: 6832-9521

liandoklianchuk@gmail.comhttps://orcid.org/0000-0003-0047-1382ГайсинаГ. О.GaisinaG. O.

Гайсина Гульназ Олеговна

119021, г. Москва, переулок Хользунова, д. 7

SPIN-код: 4522-5373

Gulnaz O. Gaisina

119021, Moscow, pereulok Holzunova 7

SPIN-код: 4522-5373

alyssiya18pennywise@gmail.comБашкирский государственный медицинский университетРоссияBashkir state medical universityRussian FederationПервый Санкт-Петербургский государственный медицинский университет им. акад. И.П. ПавловаРоссияFirst Pavlov state medical university of St. PetersburgRussian FederationРостовский государственный медицинский университетРоссияRostov state medical universityRussian Federation202220122022686146156Copyright © Хамадьянова А.У., Кузнецов К.О., Гайфуллина Э.И., Каландин Д.А., Хамидуллина Р.Р., Халитова И.Ф., Фаизов Р.М., Камалетдинова Н.О., Асланова Б.Ф., Накиева А.Г., Бурангулова Л.Э., Гайсина Г.О., 20222022Хамадьянова А.У., Кузнецов К.О., Гайфуллина Э.И., Каландин Д.А., Хамидуллина Р.Р., Халитова И.Ф., Фаизов Р.М., Камалетдинова Н.О., Асланова Б.Ф., Накиева А.Г., Бурангулова Л.Э., Гайсина Г.О.Hamadyanova A.U., Kuznetsov K.O., Gaifullina E.I., Kalandin D.A., Khamidullina R.R., Khalitova I.F., Faizov R.M., Kamaletdinova N.O., Aslanova B.F., Nakieva A.G., Burangulova L.E., Gaisina G.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.probl-endojournals.ru/jour/article/view/13148

Болезнь Паркинсона (БП) является вторым по распространенности нейродегенеративным заболеванием после болезни Альцгеймера. Имеются данные, что БП имеет более широкую распространенность среди мужчин, что свидетельствует об имеющейся роли половых гормонов в патогенезе развития заболевания. В статье представлен обзор исследований, посвященных изучению половых различий в заболеваемости и симптомах БП. Медикаментозная терапия андрогенами, предшественниками андрогенов, антиандрогенами и препаратами, модифицирующими метаболизм андрогенов, доступна для лечения различных эндокринных состояний, имея трансляционное значение для БП, но ни один из этих препаратов еще не показал достаточной эффективности. Хотя в настоящее время доказано, что БП более распространена у мужчин, чем у женщин, андрогены не всегда оказывают какое-либо влияние на симптомы или прогрессирование заболевания. Ингибиторы 5α-редуктазы показали нейропротекторную и антидискинетическую активность и нуждаются в дальнейшем исследовании. Несмотря на то что нейропротекторный эффект дутастерида наблюдался только до повреждения дофаминовых нейронов, отсутствие негативного влияния делает его привлекательным препаратом для применения у пациентов с БП благодаря его антидискинетическим свойствам.

Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease. There is evidence that PD has a wider prevalence among men, which indicates the existing role of sex hormones in the pathogenesis of the disease. The article presents an overview of studies devoted to the study of sex differences in the incidence and symptoms of PD. Drug therapy with androgens, androgen precursors, antiandrogens and drugs that modify androgen metabolism is available for the treatment of various endocrine conditions, having translational significance for PD, but none of these drugs has yet shown sufficient effectiveness. Although PD has now been proven to be more common in men than in women, androgens do not always have any effect on the symptoms or progression of the disease. 5α-reductase inhibitors have shown neuroprotective and anti-dyskinetic activity and need further investigation. Despite the fact that the neuroprotective effect of dutasteride was observed only before damage to DA neurons, the absence of a negative effect makes it an attractive drug for use in patients with PD due to its anti-dyskinetic properties.

болезнь Паркинсонатестостеронандрогеныдигидротестостеронполовые различияэстрогеныParkinson’s diseasetestosteroneandrogendihydrotestosteronesex differencesestrogensArmstrong MJ, Okun MS. Diagnosis and Treatment of Parkinson Disease: A Review. JAMA. 2020;323(6):548-560. doi: https://doi.org/10.1001/jama.2019.22360Katunina E.A., Bezdol'nyi Yu.N. Epidemiologiya bolezni Parkinsona // Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. — 2013. — T. 113. — №12. — S. 81-88.Park A, Stacy M. Non-motor symptoms in Parkinson’s disease. J Neurol. 2009;256(3):293-298. doi: https://doi.org/10.1007/s00415-009-5240-1Lesage S, Brice A. Parkinson’s disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet. 2009;18(1):48-59. doi: https://doi.org/10.1093/hmg/ddp012Meoni S, Macerollo A, Moro E. Sex differences in movement disorders. Nat Rev Neurol. 2020;16(2):84-96. doi: https://doi.org/10.1038/s41582-019-0294-xPringsheim T, Jette N, Frolkis A, Steeves TD. The prevalence of Parkinson’s disease: a systematic review and meta-analysis. Mov Disord. 2014;29(13):1583-1590. doi: https://doi.org/10.1002/mds.25945Aralbaeva A.D., Kamenova S.U., Kuzhybaeva K.K. Bolezn' Parkinsona // Vestnik Kazakhskogo Natsional'nogo meditsinskogo universiteta. — 2019. — №1. — S. 199-201.Hirsch L, Jette N, Frolkis A, Steeves T, Pringsheim T. The incidence of Parkinson’s disease: A systematic review and meta-analysis. Neuroepidemiology. 2016;46(4):292-300. doi: https://doi.org/10.1159/000445751Shulman LM, Bhat V. Gender disparities in Parkinson’s disease. Expert Rev Neurother. 2006;6(3):407-416. doi: https://doi.org/10.1586/14737175.6.3.407Swerdlow RH, Parker WD, Currie LJ, et al. Gender ratio differences between Parkinson’s disease patients and their affected relatives. Parkinsonism Relat Disord. 2001;7(2):129-133. doi: https://doi.org/10.1016/s1353-8020(00)00029-8Taylor KS, Cook JA, Counsell CE. Heterogeneity in male to female risk for Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78(8):905-906. doi: https://doi.org/10.1136/jnnp.2006.104695Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson’s disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003;157(11):1015-1022. doi: https://doi.org/10.1093/aje/kwg068Wooten GF, Currie LJ, Bovbjerg VE, et al. Are men at greater risk for Parkinson’s disease than women? J Neurol Neurosurg Psychiatry. 2004;75(4):637-639. doi: https://doi.org/10.1136/jnnp.2003.020982Haaxma CA, Bloem BR, Borm GF, et al. Gender differences in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2007;78(8):819-824. doi: https://doi.org/10.1136/jnnp.2006.103788Twelves D, Perkins KS, Counsell C. Systematic review of incidence studies of Parkinson’s disease. Mov Disord. 2003;18(1):19-31. doi: https://doi.org/10.1002/mds.10305Frentzel D, Judanin G, Borozdina O, et al. Increase of Reproductive Life Span Delays Age of Onset of Parkinson’s Disease. Front Neurol. 2017;8(2):371-377. doi: https://doi.org/10.3389/fneur.2017.00397Ragonese P, D’Amelio M, Callari G, et al. Age at menopause predicts age at onset of Parkinson’s disease. Mov Disord. 2006;21(12):2211-2214. doi: https://doi.org/10.1002/mds.21127Bourque M, Morissette M, Di Paolo T. Repurposing sex steroids and related drugs as potential treatment for Parkinson’s disease. Neuropharmacology. 2019;147(2):37-54. doi: https://doi.org/10.1016/j.neuropharm.2018.04.005Jurado-Coronel JC, Cabezas R, Ávila Rodríguez MF, et al. Sex differences in Parkinson’s disease: Features on clinical symptoms, treatment outcome, sexual hormones and genetics. Front Neuroendocrinol. 2018;50(2):18-30. doi: https://doi.org/10.1016/j.yfrne.2017.09.002Do Rego JL, Seong JY, Burel D, et al. Neurosteroid biosynthesis: enzymatic pathways and neuroendocrine regulation by neurotransmitters and neuropeptides. Front Neuroendocrinol. 2009;30(3):259-301. doi: https://doi.org/10.1016/j.yfrne.2009.05.006McEwan IJ, Brinkmann AO. Androgen physiology: Receptor and metabolic disorders. In: Endotext. South Dartmouth: MA. MDText.com, Inc; 2000.Thomas P. Membrane androgen receptors unrelated to nuclear steroid receptors. Endocrinology. 2019;160(4):772-781. doi: https://doi.org/10.1210/en.2018-00987Callewaert L, Christiaens V, Haelens A, et al. Implications of a polyglutamine tract in the function of the human androgen receptor. Biochem Biophys Res Commun. 2003;306(1):46-52. doi: https://doi.org/10.1016/s0006-291x(03)00902-1Tirabassi G, Cignarelli A, Perrini S, et al. Influence of CAG Repeat Polymorphism on the Targets of Testosterone Action. Int J Endocrinol. 2015;2015(2):1-12. doi: https://doi.org/10.1155/2015/298107Kaufman JM, Lapauw B, Mahmoud A, et al. Aging and the Male Reproductive System. Endocr Rev. 2019;40(4):906-972. doi: https://doi.org/10.1210/er.2018-00178Harman SM, Metter EJ, Tobin JD, Pearson J, Blackman MR; Baltimore longitudinal study of aging. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab. 2001;86(2):724-731. doi: https://doi.org/10.1210/jcem.86.2.7219Okun MS, McDonald WM, DeLong MR. Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidity. Arch Neurol. 2002;59(5):807-811. doi: https://doi.org/10.1001/archneur.59.5.807Okun MS, Crucian GP, Fischer L, et al. Testosterone deficiency in a Parkinson’s disease clinic: results of a survey. J Neurol Neurosurg Psychiatry. 2004;75(1):165-166.Luchetti S, Bossers K, Frajese GV, Swaab DF. Neurosteroid biosynthetic pathway changes in substantia nigra and caudate nucleus in Parkinson’s disease. Brain Pathol. 2010;20(5):945-951. doi: https://doi.org/10.1111/j.1750-3639.2010.00396.xOkun MS, Wu SS, Jennings D, et al. Testosterone level and the effect of levodopa and agonists in early Parkinson disease: results from the INSPECT cohort. J Clin Mov Disord. 2014;1(1):8. doi: https://doi.org/10.1186/2054-7072-1-8Chung SD, Lin HC, Tsai MC, et al. Androgen deprivation therapy did not increase the risk of Alzheimer’s and Parkinson’s disease in patients with prostate cancer. Andrology. 2016;4(3):481-485. doi: https://doi.org/10.1111/andr.12187Young James W. S. Sutradhar Rinku Rangrej Jagadish Marras Connie Fleshner Neil Alibhai Shabbir M. H. Androgen deprivation therapy and the risk of parkinsonism in men with prostate cancer World Journal of Urology 2017 02 1417 1423 35 9 10.1007/s00345-017-2010-zKhasnavis S, Ghosh A, Roy A, Pahan K. Castration induces Parkinson disease pathologies in young male mice via inducible nitric-oxide synthase. J Biol Chem. 2013;288(29):20843-20855. doi: 10.1074/jbc.M112.443556.Murray HE, Pillai AV, McArthur SR, et al. Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females. Neuroscience. 2003;116(1):213-222. doi: https://doi.org/10.1016/s0306-4522(02)00578-xTamás A, Lubics A, Lengvári I, Reglodi D. Effects of age, gender, and gonadectomy on neurochemistry and behavior in animal models of Parkinson’s disease. Endocrine. 2006;29(2):275-287. doi: https://doi.org/10.1385/ENDO:29:2:275Cunningham RL, Macheda T, Watts LT, et al. Androgens exacerbate motor asymmetry in male rats with unilateral 6-hydroxydopamine lesion. Horm Behav. 2011;60(5):617-624. doi: https://doi.org/10.1016/j.yhbeh.2011.08.012Antzoulatos E, Jakowec MW, Petzinger GM, Wood RI. MPTP Neurotoxicity and Testosterone Induce Dendritic Remodeling of Striatal Medium Spiny Neurons in the C57Bl/6 Mouse. Parkinsons Dis. 2011;2011(1):1-10. doi: https://doi.org/10.4061/2011/138471Dluzen DE. Effects of testosterone upon MPTP-induced neurotoxicity of the nigrostriatal dopaminergic system of C57/B1 mice. Brain Res. 1996;715(1-2):113-118. doi: https://doi.org/10.1016/0006-8993(95)01566-3.Litim N, Bourque M, Al Sweidi S, et al. The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson’s disease. Neuropharmacology. 2015;97(1):86-94. doi: https://doi.org/10.1016/j.neuropharm.2015.05.015Litim N, Morissette M, Caruso D, et al. Effect of the 5α-reductase enzyme inhibitor dutasteride in the brain of intact and parkinsonian mice. J Steroid Biochem Mol Biol. 2017;174:242-256. doi: https://doi.org/10.1016/j.jsbmb.2017.09.021Ruffoli R, Giambelluca MA, Scavuzzo MC, et al. MPTPinduced Parkinsonism is associated with damage to Leydig cells and testosterone loss. Brain Res. 2008;1229:218-223. doi: https://doi.org/10.1016/j.brainres.2008.06.116Allen JA, Diemer T, Janus P, et al. Bacterial endotoxin lipopolysaccharide and reactive oxygen species inhibit Leydig cell steroidogenesis via perturbation of mitochondria. Endocrine. 2004;25(3):265-275. doi: https://doi.org/10.1385/ENDO:25:3:265Lee SY, Gong EY, Hong CY, et al. ROS inhibit the expression of testicular steroidogenic enzyme genes via the suppression of Nur77 transactivation. Free Radic Biol Med. 2009;47(11):1591-600. doi: https://doi.org/10.1016/j.freeradbiomed.2009.09.004Melcangi RC, Caruso D, Levandis G, et al. Modifications of neuroactive steroid levels in an experimental model of nigrostriatal degeneration: potential relevance to the pathophysiology of Parkinson’s disease. J Mol Neurosci. 2012;46(1):177-183. doi: https://doi.org/10.1007/s12031-011-9570-yOkun MS, Fernandez HH, Rodriguez RL, et al. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study. Arch Neurol. 2006;63(5):729-735. doi: https://doi.org/10.1001/archneur.63.5.729Okun Michael S. Walter Benjamin L. McDonald William M. Tenover Joyce L. Green Joanne Juncos Jorge L. DeLong Mahlon R. Beneficial Effects of Testosterone Replacement for the Nonmotor Symptoms of Parkinson Disease Archives of Neurology 2003 03 1750 59 11 10.1001/archneur.59.11.1750Mitchell E, Thomas D, Burnet R. Testosterone improves motor function in Parkinson’s disease. J Clin Neurosci. 2006;13(1):133-136. doi: https://doi.org/10.1016/j.jocn.2005.02.014Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: An endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. doi: https://doi.org/10.1210/jc.2018-00229Rodrigues dos Santos Marcelo Bhasin Shalender Benefits and Risks of Testosterone Treatment in Men with Age-Related Decline in Testosterone Annual Review of Medicine 2020 11 75 91 72 1 10.1146/annurev-med-050219-034711Ekue A, Boulanger JF, Morissette M, Di Paolo T. Lack of effect of testosterone and dihydrotestosterone compared to 17beta-oestradiol in 1-methyl-4-phenyl-1,2,3,6, tetrahydropyridine-mice. J Neuroendocrinol. 2002;14(9):731-736. doi: https://doi.org/10.1046/j.1365-2826.2002.00833.xGillies GE, Murray HE, Dexter D, McArthur S. Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson’s disease. Pharmacol Biochem Behav. 2004;78(3):513-522. doi: https://doi.org/10.1016/j.pbb.2004.04.022Cui R, Kang Y, Wang L, et al. Testosterone Propionate Exacerbates the Deficits of Nigrostriatal Dopaminergic System and Downregulates Nrf2 Expression in Reserpine-Treated Aged Male Rats. Front Aging Neurosci. 2017;9(1):75-91. doi: https://doi.org/10.3389/fnagi.2017.00172Frolova G.A. Sravnitel'naya kharakteristika effektov blokirovaniya retseptorov polovykh gormonov u samtsov i samok belykh krys s raznym urovnem aktivnosti na nekotorye pokazateli povedeniya // Vіsnik problem bіologії і meditsini. — 2013. — T. 2. — №3. — S. 235-239.Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology. 1997;138(3):863-870. doi: https://doi.org/10.1210/endo.138.3.4979Bourque M, Morissette M, Di Paolo T. Raloxifene activates G protein-coupled estrogen receptor 1/Akt signaling to protect dopamine neurons in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine mice. Neurobiol Aging. 2014;35(10):2347-2356. doi: https://doi.org/10.1016/j.neurobiolaging.2014.03.017Nitkowska M, Tomasiuk R, Czyżyk M, Friedman A. Prolactin and sex hormones levels in males with Parkinson’s disease. Acta Neurol Scand. 2015;131(6):411-416. doi: https://doi.org/10.1111/ane.12334Georgianos PI, Vaios V, Eleftheriadis T, et al. Mineralocorticoid Antagonists in ESRD: An Overview of Clinical Trial Evidence. Curr Vasc Pharmacol. 2017;15(6):599-606. doi: https://doi.org/10.2174/1570161115666170201113817Hermidorff MM, Faria Gde O, Amâncio Gde C, et al. Nongenomic effects of spironolactone and eplerenone in cardiomyocytes of neonatal Wistar rats: do they evoke cardioprotective pathways? Biochem Cell Biol. 2015;93(1):83-93. doi: https://doi.org/10.1139/bcb-2014-0110Teive HA, Munhoz RP, Werneck LC. Worsening of motor symptoms and gynecomastia during spironolactone treatment in a patient with Parkinson’s disease and congestive heart failure. Mov Disord. 2007;22(11):1678-1679. doi: https://doi.org/10.1002/mds.21579Majidi Zolbanin N, Zolali E, Mohajjel Nayebi A. Testosterone replacement attenuates haloperidol-induced catalepsy in male rats. Adv Pharm Bull. 2014;4(3):237-241. doi: https://doi.org/10.5681/apb.2014.034Cunningham RL, Giuffrida A, Roberts JL. Androgens induce dopaminergic neurotoxicity via caspase-3-dependent activation of protein kinase Cdelta. Endocrinology. 2009;150(12):5539-5548. doi: https://doi.org/10.1210/en.2009-0640Duong P, Tenkorang MAA, Trieu J, et al. Neuroprotective and neurotoxic outcomes of androgens and estrogens in an oxidative stress environment. Biol Sex Differ. 2020;11(1):12. doi: https://doi.org/10.1186/s13293-020-0283-1Haussermann Peter Goecker David Beier Klaus Schroeder Stefan Low-Dose Cyproterone Acetate Treatment of Sexual Acting Out in Men With Dementia International Psychogeriatrics 2004 03 181 186 15 2 10.1017/s104161020300886xGiatti S, Diviccaro S, Falvo E, et al. Physiopathological role of the enzymatic complex 5α-reductase and 3α/β-hydroxysteroid oxidoreductase in the generation of progesterone and testosterone neuroactive metabolites. Front Neuroendocrinol. 2020;57:100836. doi: https://doi.org/10.1016/j.yfrne.2020.100836Melcangi RC, Garcia-Segura LM, Mensah-Nyagan AG. Neuroactive steroids: state of the art and new perspectives. Cell Mol Life Sci. 2008;65(5):777-797. doi: https://doi.org/10.1007/s00018-007-7403-5Castelli MP, Casti A, Casu A, et al. Regional distribution of 5α-reductase type 2 in the adult rat brain: an immunohistochemical analysis. Psychoneuroendocrinology. 2013;38(2):281-293. doi: https://doi.org/10.1016/j.psyneuen.2012.06.008Finn DA, Beadles-Bohling AS, Beckley EH, et al. A new look at the 5alpha-reductase inhibitor finasteride. CNS Drug Rev. 2006;12(1):53-76. doi: https://doi.org/10.1111/j.1527-3458.2006.00053.xXu Y, Dalrymple SL, Becker RE, et al. Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clin Cancer Res. 2006;12(13):4072-4079. doi: https://doi.org/10.1158/1078-0432.CCR-06-0184Paba S, Frau R, Godar SC, et al. Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders. Curr Pharm Des. 2011;17(2):151-167. doi: https://doi.org/10.2174/138161211795049589Bortolato Marco Cannas Antonino Solla Paolo Bini Valentina Puligheddu Monica Marrosu Francesco Finasteride Attenuates Pathological Gambling in Patients With Parkinson Disease Journal of Clinical Psychopharmacology 2012 04 424 425 32 3 10.1097/jcp.0b013e3182549c2aFrau R, Savoia P, Fanni S, et al. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson’s disease. Exp Neurol. 2017;291(4):1-7. doi: https://doi.org/10.1016/j.expneurol.2017.01.012Fanni S, Scheggi S, Rossi F, et al. 5alpha-reductase inhibitors dampen L-DOPA-induced dyskinesia via normalization of dopamine D1-receptor signaling pathway and D1-D3 receptor interaction. Neurobiol Dis. 2019;121(4):120-130. doi: https://doi.org/10.1016/j.nbd.2018.09.018Frau R, Mosher LJ, Bini V, et al. The neurosteroidogenic enzyme 5α-reductase modulates the role of D1 dopamine receptors in rat sensorimotor gating. Psychoneuroendocrinology. 2016;63(4):59-67. doi: https://doi.org/10.1016/j.psyneuen.2015.09.014Fedotova Yu.O. Vliyanie agonista i antagonista D2-tipa dofaminovykh retseptorov na obuchenie pri raznom urovne androgenov u krys // Orbital'. — 2017. — №1. — S. 38-48.Masoud ST, Vecchio LM, Bergeron Y, et al. Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits. Neurobiol Dis. 2015;74(4):66-75. doi: https://doi.org/10.1016/j.nbd.2014.10.016Vallée M. Neurosteroids and potential therapeutics: Focus on pregnenolone. J Steroid Biochem Mol Biol. 2016;160(4):78-87. doi: https://doi.org/10.1016/j.jsbmb.2015.09.030Azuma T, Matsubara T, Shima Y, et al. Neurosteroids in cerebrospinal fluid in neurologic disorders. J Neurol Sci. 1993;120(1):87-92. doi: https://doi.org/10.1016/0022-510x(93)90030-3Bélanger N, Grégoire L, Bédard P, Di Paolo T. Estradiol and dehydroepiandrosterone potentiate levodopainduced locomotor activity in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine monkeys. Endocrine. 2003;21(1):97-101. doi: https://doi.org/10.1385/endo:21:1:97Bélanger N, Grégoire L, Bédard PJ, Di Paolo T. DHEA improves symptomatic treatment of moderately and severely impaired MPTP monkeys. Neurobiol Aging. 2006;27(11):1684-1693. doi: https://doi.org/10.1016/j.neurobiolaging.2005.09.028D'Astous Myreille Morissette Marc Tanguay Bastien Callier Sophie Di Paolo Th�r�se Dehydroepiandrosterone (DHEA) such as 17?-estradiol prevents MPTP-induced dopamine depletion in mice Synapse 2002 11 10 14 47 1 10.1002/syn.10145Frau R, Miczán V, Traccis F, et al. Prenatal THC exposure produces a hyperdopaminergic phenotype rescued by pregnenolone. Nat Neurosci. 2019;22(12):1975-1985. doi: https://doi.org/10.1038/s41593-019-0512-2Davison SL, Bell R, Donath S, et al. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab. 2005;90(7):3847-3853. doi: https://doi.org/10.1210/jc.2005-0212Collier TJ, Kanaan NM, Kordower JH. Ageing as a primary risk factor for Parkinson’s disease: evidence from studies of non-human primates. Nat Rev Neurosci. 2011;12(6):359-366. doi: https://doi.org/10.1038/nrn3039Collier TJ, Kanaan NM, Kordower JH. Aging and Parkinson’s disease: Different sides of the same coin? Mov Disord. 2017;32(7):983-990. doi: https://doi.org/10.1002/mds.27037Reeve A, Simcox E, Turnbull D. Ageing and Parkinson’s disease: why is advancing age the biggest risk factor? Ageing Res Rev. 2014;14(100):19-30. doi: https://doi.org/10.1016/j.arr.2014.01.004Darbin O. The aging striatal dopamine function. Parkinsonism Relat Disord. 2012;18(5):426-432. doi: https://doi.org/10.1016/j.parkreldis.2011.11.025Rollo CD. Dopamine and aging: intersecting facets. Neurochem Res. 2009;34(4):601-629. doi: https://doi.org/10.1007/s11064-008-9858-7Erixon-Lindroth N, Farde L, Wahlin TB, et al. The role of the striatal dopamine transporter in cognitive aging. Psychiatry Res. 2005;138(1):1-12. doi: https://doi.org/10.1016/j.pscychresns.2004.09.005Volkow ND, Gur RC, Wang GJ, et al. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am J Psychiatry. 1998;155(3):344-349. doi: https://doi.org/10.1176/ajp.155.3.344Volkow ND, Logan J, Fowler JS, et al. Association between agerelated decline in brain dopamine activity and impairment in frontal and cingulate metabolism. Am J Psychiatry. 2000;157(1):75-80. doi: https://doi.org/10.1176/ajp.157.1.75Jiang N, Bo H, Song C, et al. Increased vulnerability with aging to MPTP: the mechanisms underlying mitochondrial dynamics. Neurol Res. 2014;36(8):722-732. doi: https://doi.org/10.1179/1743132813Y.0000000296McCormack AL, Di Monte DA, Delfani K, et al. Aging of the nigrostriatal system in the squirrel monkey. J Comp Neurol. 2004;471(4):387-395. doi: https://doi.org/10.1002/cne.20036Lang AE. The progression of Parkinson disease: a hypothesis. Neurology. 2007;68(12):948-952. doi: https://doi.org/10.1212/01.wnl.0000257110.91041.5dJenner P. Molecular mechanisms of L-DOPA-induced dyskinesia. Nat Rev Neurosci. 2008;9(9):665-677. doi: https://doi.org/10.1038/nrn2471Siderowf A, Stern M. Update on Parkinson disease. Ann Intern Med. 2003;138(8):651-658. doi: https://doi.org/10.7326/0003-4819-138-8-200304150-00013Gundersen V. Parkinson’s Disease: Can Targeting Inflammation Be an Effective Neuroprotective Strategy? Front Neurosci. 2021;14(4):78-87. doi: https://doi.org/10.3389/fnins.2020.580311Smeyne RJ, Noyce AJ, Byrne M, et al. Infection and Risk of Parkinson’s Disease. J Parkinsons Dis. 2021;11(1):31-43. doi: https://doi.org/10.3233/JPD-202279Sadasivan S, Sharp B, Schultz-Cherry S, Smeyne RJ. Synergistic effects of influenza and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) can be eliminated by the use of influenza therapeutics: experimental evidence for the multi-hit hypothesis. NPJ Park Dis. 2017;3(1):18. doi: https://doi.org/10.1038/s41531-017-0019-zCadegiani FA. Repurposing existing drugs for COVID-19: an endocrinology perspective. BMC Endocr Disord. 2020;20(1):149. doi: https://doi.org/10.1186/s12902-020-00626-0Cadegiani FA, McCoy J, Gustavo Wambier C, Goren A. Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial – Biochemical). Cureus. 2021;3(1):18. doi: https://doi.org/10.7759/cureus.13047McCoy J. Cadegiani F.A. Wambier C.G. Herrera S. Vaño‐Galván S. Mesinkovska N.A. Ramos P.M. Shapiro J. Sinclair R. Tosti A. Goren A. 5‐alpha‐reductase inhibitors are associated with reduced frequency of COVID‐19 symptoms in males with androgenetic alopecia Journal of the European Academy of Dermatology and Venereology 2020 11 35 4 10.1111/jdv.17021Lazzeri M, Duga S, Azzolini E, et al. Humanitas COVID-19 Task Force, The Humanitas Gavazzeni COVID-19 Task Force. Impact of chronic exposure to 5-alpha reductase inhibitors on the risk of hospitalization for COVID-19: a case-control study in male population from two COVID-19 regional centers of Lombardy, Italy. Minerva Urol Nephrol. 2022;74(1):77-84. doi: https://doi.org/10.23736/S2724-6051.20.04081-3Tauchen J, Jurášek M, Huml L, Rimpelová S. Medicinal Use of Testosterone and Related Steroids Revisited. Molecules. 2021;26(4):1032. doi: https://doi.org/10.3390/molecules26041032Gorczyca Damian Kwiatkowska Dorota Duality nature of Selective Androgen Receptor Modulators and Specific Steroids Substance Disaster and Emergency Medicine Journal 2019 10 60 62 4 2 10.5603/demj.2019.0012

The authors declare that there are no conflicts of interest present.